Crystal's MCW Coder Hub🧬 ICD-10-CM H40.61X3 — Glaucoma Secondary to Drugs, Right Eye, Severe Stage
Billable Code Confirmed — 7 Characters Complete
ICD-10 CM H40.61X3 is a valid, billable 7-character ICD-10-CM code for FY2025. [web:217][web:218][web:209] Structure:
H40(glaucoma) +.6(secondary to drugs) +1(right eye) +X(structural placeholder) +3(severe stage). Complete and current.
Non-Billable Parent Codes — Do Not Submit
- ❌
H40.61— 5-character header — non-billable- ❌
H40.6— 4-character header — non-billable
🚨 MANDATORY ADDITIONAL CODE — T-Code Required
🔴 Severe Stage = Vision-Threatening — Fixation Is at Risk
H40.61X3 represents the highest tier of drug-induced glaucomatous damage short of absolute glaucoma. Visual field loss is within 5° of central fixation in at least one hemifield. Surgical intervention is the standard of care — documentation must clearly reflect the treatment plan, surgical rationale, and the urgency of IOP control.
🔍 Code Description
ICD-10 CM H40.61X3 classifies glaucoma secondary to drug therapy, right eye, at the severe stage — advanced glaucomatous optic neuropathy and visual field loss caused by a pharmacologic agent, where the mean deviation on Humphrey Visual Field 24-2 testing is worse than -12 dB and/or field loss has encroached within 5° of central fixation in at least one hemifield. At this stage, central visual acuity — the last domain patients subjectively notice — is directly threatened. The patient faces potential legal blindness in the affected eye if IOP is not aggressively controlled.
The severe stage is the surgical decision point. While mild (H40.61X1) and moderate (H40.61X2) stages accommodate a deliberate, stepwise approach to medical escalation and elective laser procedures, H40.61X3 demands urgent, definitive IOP reduction — typically trabeculectomy, glaucoma drainage device (tube shunt), or endoscopic cyclophotocoagulation — with the goal of achieving very low target IOPs (≤12-15 mmHg) to halt progression before the remaining visual field is consumed.
📊 Severe Stage — Defining Criteria and What Changed from Moderate
The Two Triggers for Severe Stage
H40.61X3 is assigned when EITHER criterion is met:
- HVF 24-2 Mean Deviation worse than -12 dB — quantity of field loss
- Visual field loss within 5° of central fixation in ≥1 hemifield — location of field loss threatening fixation
A patient can have an MD of -10 dB (still in moderate range quantitatively) but if the field loss is located within 5° of fixation → severe stage applies. Location at the fovea matters as much as quantity.
| Feature | Moderate — H40.61X2 | Severe — H40.61X3 |
|---|---|---|
| HVF Mean Deviation | -6 to -12 dB | Worse than -12 dB |
| Fixation threat | NOT within 5° of fixation in both hemifields | Within 5° of fixation in ≥1 hemifield |
| OCT RNFL | Moderate thinning | Advanced loss — near or complete sector dropout |
| Central VA | Usually preserved | Threatened — may be reduced; 20/200 risk |
| Functional impact | Peripheral vision gaps | Significant disability — reading, driving impaired |
| Monitoring frequency | Every 3-6 months HVF | Every 3 months HVF AND OCT |
| IOP target | ≥30% reduction; 15-18 mmHg | ≥40% reduction; ≤12-15 mmHg — aggressive |
| Primary intervention | SLT + MIGS consideration | Trabeculectomy or tube shunt — surgical urgency |
| MIGS role | Strong indication | MIGS alone usually insufficient — filtering surgery needed |
| Disability documentation | Driving safety discussion | Legal blindness assessment if VA reduced; disability coding |
🌳 Stage Context — End of the H40.61X Continuum
H40.61 Right Eye — Glaucoma Secondary to Drugs ❌ Non-billable
│
├── H40.61X0 Stage unspecified ⚠️ Query
├── H40.61X1 Mild — MD > -6 dB
├── H40.61X2 Moderate — MD -6 to -12 dB
├── H40.61X3 SEVERE — MD < -12 dB and/or within 5° of fixation ← THIS CODE ✅
├── H40.61X4 Indeterminate
│
└── ⛔ H44.511 Absolute glaucoma, right eye — Excludes 1
No light perception — end stage beyond H40.61X3
CANNOT be coded simultaneously with H40.61X3
H44.511 — Absolute Glaucoma — Know This Boundary
When the right eye has no light perception (NLP) from end-stage glaucoma, the code transitions to H44.511 (Absolute glaucoma, right eye) — which carries an Excludes 1 relationship with H40.61X3. They cannot be coded together. The progression is:
- Active severe glaucoma with remaining vision → H40.61X3
- No light perception, end-stage, no active treatment possible → H44.511
H40.61X3 implies there is still residual visual function worth protecting — surgical intervention is still meaningful. H44.511 represents the end state where vision is gone. This distinction drives both the code selection AND the medical necessity documentation for any proposed procedures.
🔬 Severe Stage — IOP Targets and Why They Matter
At severe drug-induced glaucoma, the remaining optic nerve fibers are extremely vulnerable. Even small IOP fluctuations that would be tolerable at mild or moderate stage can devastate the thin residual RNFL.
Target IOP by Stage — The Full Picture
| Stage | IOP Target | Reduction Goal | Rationale |
|---|---|---|---|
| Mild H40.61X1 | 18-22 mmHg | ≥20% from baseline | Early damage — moderate control sufficient |
| Moderate H40.61X2 | 15-18 mmHg | ≥30% from baseline | Significant damage — tighter control needed |
| Severe H40.61X3 | ≤12-15 mmHg | ≥40% from baseline | Advanced damage — aggressive, near-physiologic IOP required |
Document the Target IOP in the Note at Severe Stage
At H40.61X3, the physician’s documentation of a specific target IOP (e.g., “target IOP ≤12 mmHg given advanced field loss”) is critical for:
- Supporting medical necessity for aggressive treatment escalation
- Justifying surgical intervention when medications fail to reach target
- Defending the frequency of monitoring visits to payers
- Establishing the clinical baseline for progression assessment post-operatively
🏥 Surgical Interventions — Primary Management at Severe Stage
At severe stage, MIGS is generally insufficient for achieving the low target IOPs required. The standard of care shifts to filtration surgery.
Filtering Surgeries — Primary at Severe Stage
| Procedure | CPT | IOP Reduction | When Preferred |
|---|---|---|---|
| Trabeculectomy | 66170-RT (no antifibrotics) / 66172-RT (with antifibrotics) | 40-50% reduction; often reaches low teens | First-line incisional surgery for severe glaucoma with adequate conjunctiva |
| Tube shunt (Ahmed valve) | 66180-RT | 35-45% reduction; IOP floor ~10-12 mmHg | Prior failed trabeculectomy; inadequate conjunctiva; high-risk eyes |
| Tube shunt (Baerveldt) | 66180-RT | 40-50%; lower long-term IOP than Ahmed | When very low IOP target required; high-volume drainage |
| Canaloplasty | 66174-RT | 30-40% reduction | Open-angle severe; no bleb; lower risk profile |
Laser and Destructive Procedures — When Filtering Surgery Not Feasible
| Procedure | CPT | When Used |
|---|---|---|
| Endoscopic cyclophotocoagulation (ECP) | 66711-RT | Combined with cataract surgery; refractory cases |
| Transscleral CPC | 66711-RT | End-stage or near-end-stage; poor surgical candidates |
| SLT | 65855-RT | Adjunct — rarely sufficient as sole treatment at severe stage; may augment post-surgical management |
Trabeculectomy vs. Tube Shunt at H40.61X3 — The Tipping Point
The Tube vs. Trabeculectomy (TVT) Study informs the choice at severe stage. For eyes with prior surgery or difficult conjunctiva, tube shunts have comparable efficacy to trabeculectomy with a better long-term safety profile. For primary severe glaucoma with virgin conjunctiva, trabeculectomy with mitomycin C remains the gold standard for achieving very low IOPs. Document the clinical rationale for the procedure selected — prior surgical history, conjunctival status, and target IOP all factor into the choice and support medical necessity.
Post-Operative Coding at Severe Stage [web:221]
After filtering surgery for H40.61X3, the same diagnosis code continues through the global period and beyond. Stage may be reassessed post-operatively:
- If IOP is controlled and fields stabilize → H40.61X3 continues (damage doesn’t reverse)
- If additional progression documented → H40.61X3 continues (severity doesn’t downgrade)
- If NLP develops → transition to H44.511 (Excludes 1 — absolute glaucoma)
Glaucoma Stage Never Downgrades
Once a patient is coded at severe (H40.61X3), the stage never reverses to moderate or mild — glaucomatous optic nerve damage is permanent. Even if IOP is perfectly controlled post-operatively and fields stabilize, the patient remains at severe stage. The stage reflects cumulative structural and functional damage, not current IOP. The code may change only if the staging criterion changes due to further progression — or if the eye reaches absolute end stage (H44.511).
💰 Vision Loss and Disability Coding at Severe Stage
At H40.61X3, central vision may be compromised. When VA is documented as reduced, additional codes apply:
| Condition | ICD-10-CM Code | When to Add |
|---|---|---|
| Legal blindness, right eye (VA <20/200 or field <20°) | H54.411 | When VA is documented ≤20/200 in right eye |
| Low vision, right eye (VA 20/70-20/200) | H54.511 | When VA is documented 20/70-20/200 |
| Profound visual impairment, right eye | H54.1x | Near-total vision loss, light perception only |
Visual Impairment Codes — Add Only When VA Is Explicitly Documented
Do NOT assume visual impairment from the severe glaucoma stage alone. Central VA can be preserved even at severe stage (patients may have dense field loss but intact central acuity if the fovea is spared). Add H54.x codes only when the physician documents the VA level and it meets the classification criteria for low vision or legal blindness. Snellen VA documentation from the encounter is required.
🔗 Related ICD-10-CM Codes
H40.61X Family — Right Eye, Complete Stage Map
| Code | Description | MD Threshold |
|---|---|---|
| H40.61X0 | Right eye, stage unspecified | Not documented ⚠️ |
| H40.61X1 | Right eye, mild stage | Better than -6 dB |
| H40.61X2 | Right eye, moderate stage | -6 to -12 dB |
| H40.61X3 | Right eye, severe stage ← This Code | Worse than -12 dB or within 5° fixation |
| H40.61X4 | Right eye, indeterminate stage | Cannot be staged |
Cross-Laterality — Severe Stage
| Code | Description |
|---|---|
| H40.62X3 | Glaucoma secondary to drugs, left eye, severe stage |
| H40.63X3 | Glaucoma secondary to drugs, bilateral, severe stage |
Absolute End-Stage (Post-Severe)
| Code | Description | Relationship |
|---|---|---|
| H44.511 | Absolute glaucoma, right eye | Excludes 1 with H40.61X3 — NLP, end-stage; cannot code with H40.61X3 |
Mandatory Additional Code
| Code | Use When |
|---|---|
| T38.0X5A | First visit documenting severe stage |
| T38.0X5D | All ongoing monitoring and treatment visits ← Most common |
Common Co-Codes at Severe Stage
| Code | Description | Relevance |
|---|---|---|
| H54.411 | Legal blindness, right eye | If VA ≤20/200 from severe glaucoma |
| H54.511 | Low vision, right eye | If VA 20/70-20/200 |
| Z79.52 | Long-term systemic steroid use | Chronic steroid exposure documentation |
| H26.13 | Posterior subcapsular cataract | Steroid-induced PSC — concurrent |
| H35.3221 | Wet AMD right eye, active CNV | If Ozurdex was the steroid causing SIG |
| E11.3511 | T2DM with DME, right eye | If Ozurdex for DME was the cause |
🛠️ CPT Templates at Severe Stage
Template A: Severe SIG — Monitoring Visit (Outpatient)
| Code | Description | Notes |
|---|---|---|
| 92014 | Comprehensive exam, established | Full glaucoma evaluation |
| 92083 | Extended HVF 24-2 SITA Standard | Every 3 months at severe stage |
| 92133 | OCT optic nerve/RNFL, right eye | Every 3-6 months — covered per CMS LCD A56916 |
| H40.61X3 | Primary diagnosis | Document HVF MD value; field loss location re: fixation |
| T38.0X5D | Required additional | Subsequent encounter |
Template B: Trabeculectomy for Severe Drug-Induced Glaucoma
| Code | Description | Notes |
|---|---|---|
| 66172-RT | Trabeculectomy with antifibrotics (MMC) | Standard for severe SIG — MMC reduces bleb failure |
| 92014 | Pre-op exam | |
| H40.61X3 | Primary Dx | Supports surgical medical necessity |
| T38.0X5D | Required additional | |
| Document | Target IOP, failed medical/laser history | Medical necessity foundation |
Template C: Tube Shunt for Refractory Severe SIG
| Code | Description | Notes |
|---|---|---|
| 66180-RT | Aqueous drainage device implant | Ahmed or Baerveldt — refractory or prior failed trabeculectomy |
| H40.61X3 | Primary Dx | Severe stage supports tube shunt necessity |
| T38.0X5D | Required additional |
OCT Coverage Confirmed for H40.61X3 at CMS
CMS LCD Article A56916 explicitly lists H40.61X3 as a covered diagnosis for 92133 (OCT of the optic nerve/RNFL). At severe stage, every 3-month OCT monitoring is supported by both clinical guidelines and confirmed LCD coverage. Document the frequency rationale: “severe stage glaucoma — quarterly monitoring per guideline.”
💊 Coding Scenarios
Scenario 1 — Progression from Moderate to Severe (Code Change Visit)
Clinical Vignette: Patient with known drug-induced glaucoma OD (previously H40.61X2) on latanoprost + brimonidine + dorzolamide returns. IOP 19 mmHg despite triple therapy. HVF 24-2 OD: MD now -14.6 dB (was -8.3 dB). New field loss approaching fixation — within 3° of central fixation superiorly. OCT RNFL: near-complete superior sector loss. Physician impression: “Progressed to severe stage drug-induced glaucoma OD — maximum medical therapy failing. Scheduling trabeculectomy.”
ICD-10-CM — Stage Upgrade:
- H40.61X3 — Glaucoma secondary to drugs, right eye, severe stage (progression documented — MD -14.6 dB AND within 5° of fixation = severe)
- T38.0X5D — Adverse effect of glucocorticoids, subsequent encounter (drug cause persists)
Document Both Triggers When Both Are Present
This patient meets BOTH severe stage criteria: MD worse than -12 dB AND field loss within 5° of fixation. When both are present, document both in the note — it reinforces the severe-stage coding and strengthens the surgical medical necessity argument.
Scenario 2 — Severe SIG + Trabeculectomy Performed
Clinical Vignette: The same patient from Scenario 1 returns for trabeculectomy with MMC, right eye. IOP pre-op: 22 mmHg on triple drops. Post-op day 1: IOP 6 mmHg, formed bleb, no hypotony maculopathy. Impression: Trabeculectomy with MMC, right eye — successful bleb formation. H40.61X3 continues as the diagnosis — severity does not change post-operatively.
ICD-10-CM:
- H40.61X3 — Glaucoma secondary to drugs, right eye, severe stage (unchanged — surgery treats the glaucoma; it does not reverse the stage)
- T38.0X5D — Adverse effect of glucocorticoids, subsequent encounter
CPT:
- 66172-RT — Trabeculectomy with antifibrotics (MMC), right eye
- 92014 — Pre-op comprehensive exam
- Append RT to unilateral codes
Scenario 3 — Severe SIG with Legal Blindness (Full Code Set)
Clinical Vignette: An 80-year-old male with chronic oral prednisone for pemphigus vulgaris developed severe steroid-induced glaucoma OD. Despite trabeculectomy 2 years ago, IOP control has been suboptimal. Current VA OD: 20/400 (legal blindness). HVF: unable to complete — only central island remaining, MD estimated at -22 dB. OCT RNFL OD: near-total loss. Some light perception preserved — not absolute glaucoma. Physician impression: “Severe drug-induced glaucoma OD — VA legally blind OD — considering tube shunt.”
ICD-10-CM:
- H40.61X3 — Glaucoma secondary to drugs, right eye, severe stage (MD -22 dB, near-total field loss; NLP NOT present — still H40.61X3, not H44.511)
- T38.0X5D — Adverse effect of glucocorticoids, subsequent encounter (prednisone — ongoing)
- H54.411 — Legal blindness, right eye (VA 20/400 — below 20/200 threshold — right eye legally blind)
- L10.0 — Pemphigus vulgaris (underlying condition requiring prednisone — documents why steroid cannot stop)
H40.61X3 + H54.411 — Not Redundant, Both Required
H40.61X3 documents the cause of the vision loss (severe glaucoma). H54.411 documents the degree of vision loss (legal blindness). They are complementary, not redundant. Including H54.411 adds critical clinical context — this patient is functionally blind in the right eye — and supports the medical necessity documentation for escalated surgical intervention.
⚠️ Key Differences Across the H40.61X Severity Spectrum
| Feature | Mild H40.61X1 | Moderate H40.61X2 | Severe H40.61X3 |
|---|---|---|---|
| HVF MD | > -6 dB | -6 to -12 dB | < -12 dB |
| Fixation | Not threatened | Not threatened in both hemifields | Within 5° in ≥1 hemifield |
| OCT RNFL | Early thinning | Moderate thinning | Advanced / near-complete loss |
| IOP target | 18-22 mmHg | 15-18 mmHg | ≤12-15 mmHg |
| Primary Rx | Medical + SLT consider | Medical + SLT/MIGS | Trabeculectomy / tube shunt |
| MIGS role | Consideration | Strong indication | Generally insufficient alone |
| Monitoring | 6-12 months HVF | 3-6 months HVF | Every 3 months HVF + OCT |
| Disability | Unlikely | Driving safety discussion | Legal blindness possible; assess H54.x |
| T-code | T38.0X5A/D | T38.0X5A/D | T38.0X5A/D — same |
⚠️ Coding Pitfalls and Tips
| Pitfall or Tip | |
|---|---|
| ❌ | Never submit H40.61X3 without T38.0X5x T-code — mandatory at every encounter [web:217] |
| ❌ | Never code H40.61X3 and H44.511 simultaneously — Excludes 1; if NLP → H44.511 replaces H40.61X3 |
| ❌ | Never downgrade from severe to moderate — glaucomatous damage is irreversible; stage never decreases |
| ❌ | Never assume central VA is reduced — add H54.411/H54.511 ONLY when VA is explicitly documented at legal blindness / low vision threshold |
| ❌ | Never use MIGS codes as the sole surgical documentation at severe stage without explaining why filtering surgery was deferred — payer scrutiny expected |
| ✅ | Severe = MD worse than -12 dB OR within 5° of fixation — either criterion alone triggers severe; document which one (or both) applies [web:217] |
| ✅ | H40.61X3 confirmed on CMS LCD A56916 as covered Dx for 92133 OCT — quarterly monitoring supported [web:218] |
| ✅ | T38.0X5D at all monitoring/treatment visits; T38.0X5A only at initial severe-stage diagnosis |
| ✅ | Document target IOP explicitly — “target IOP ≤12 mmHg given severe stage” — this is the backbone of surgical medical necessity |
| ✅ | Document why steroid cannot be discontinued — at severe stage this is medico-legally critical |
| ✅ | After trabeculectomy or tube shunt — H40.61X3 continues; severity doesn’t change post-operatively |
| ✅ | RT modifier on all unilateral right-eye CPT codes |
📚 Sources
1. ICDList.com. “ICD-10-CM Diagnosis Code H40.61X3 — Glaucoma secondary to drugs, right eye, severe stage.” Valid for submission FY2025 (Oct 1, 2024 - Sep 30, 2025). Full family H40.61X0-H40.62 confirmed. [web:217]
2. CMS LCD Article A56916 — Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI). H40.61X3 confirmed as covered diagnosis for CPT 92133. Revised December 2024. [web:218]
3. AAPC ICD-10-CM Code Range H40-H42. H40.61X3 confirmed in family listing: mild/moderate/severe/indeterminate structure. [web:209]
4. Ubie Health. “When is surgery needed for glaucoma instead of eye drops?” Surgical thresholds at severe stage — trabeculectomy and tube shunts; MIGS limitations at advanced glaucoma. [web:219]
5. Millennium Eye. “Addressing Remaining Unmet Needs in Glaucoma Management.” MIGS vs. filtering surgery decision framework; maximum medical therapy threshold. [web:220]
6. PMC / NCBI. “The basics of good postoperative care after glaucoma surgery.” Post-trabeculectomy management — IOP targets, bleb care, antimetabolite use. [web:221]
7. Hodapp E, Parrish RK, Anderson DR. Clinical Decisions in Glaucoma. Mosby: 1993. HPA severe-stage criteria — MD worse than -12 dB; field loss within 5° of fixation.
8. See H40.61X1 for full citation list covering T-code mechanics, steroid pathophysiology, adverse effect coding framework, and complete CPT template set.